Navigation Links
Taking Blood Pressure Drugs at Bedtime May Boost Effectiveness
Date:10/8/2010

and also included a morning treatment comparison group to properly evaluate the merits of the bedtime dosing strategy."

People most likely to benefit from taking their pills at night include those whose high blood pressure occurs secondary to another condition, such as metabolic syndrome, type 2 diabetes, sleep apnea or other sleep disorders, heart failure or kidney disease, said Smolensky.

"They are most likely to be nondippers," he said.

However, those who now take their pills in the morning should not begin taking them at night without their doctor's knowledge, said Hermida. "There is a risk for nocturnal hypotension [abnormally low blood pressure] which could increase the risk of stroke."

More information

There's more on maintaining healthy blood pressure at the American Heart Association.

SOURCES: Ramon C. Hermida, Ph.D., director, Bioengineering and Chronobiology Labs, University of Vigo, Spain; Michael Smolensky, adjunct professor, department of biomedical engineering, University of Texas at Austin, and editor, Chronobiology International; Oct. 5, 2010, Chronobiology International


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Texting Taking a Deadly Toll on Roads
2. 1 in 4 stroke patients stop taking prevention medication within 3 months
3. Many Stroke Patients Stop Taking Meds, Study Shows
4. Taking to the Stage to Battle Mental Illness
5. Taking music seriously
6. Taking Public Transit Might Help You Stay Slim
7. Rich Vitamins Proves Taking Vitamins Doesn't Have to be a Pill with New alternaVites
8. Many Docs Dont Mind Taking Gifts From Industry: Study
9. NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs
10. Gene mutation increases thromboembolism risk in women taking tamoxifen
11. Taking aim at metastatic lung tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Taking Blood Pressure Drugs at Bedtime May Boost Effectiveness
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... May 29, 2015 The science of ... last decade. New and more efficient methods of FUE hair ... balding patients. One of the most cutting edge hair transplant ... Restoration is the technique of extracting hair from the beard ... are performed to correct male pattern baldness. Beard ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her son, ... God does no wrong. , It’s fitting, then, that her ... titled “God Does No Wrong.” It focuses on what happens ... , “My story has a positive message about channeling ... productive, something healing,” Howse said. , “God Does No Wrong” ...
(Date:5/29/2015)... New York, New York (PRWEB) May 29, 2015 ... and distributor of patented products, announces that it has ... Chat Room, a technology patent that aims to let ... various industry experts in real time. , "This is ... Expert Chat Room " said Scott J. Cooper, CEO ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... American College of Physicians (ACP) and the Infectious Diseases ... on the importance of adult vaccination against an increasing ... by 17 other medical societies representing a range of ... Control and Prevention, 95 percent of vaccine-preventable diseases occur ...
... 19 NuVasive, Inc. (Nasdaq: NUVA ), a ... surgical treatments for the spine, announced today that Alex Lukianov, ... the 20th Annual Piper Jaffray Health Care Conference at The ... 10:30 a.m. ET. , , ...
... Microsoft Corp. today,announced that Blue Cross ... private health carrier, has saved nearly a ... system. Implemented to overhaul,incentive compensation and agent ... VUE Compensation Management, a Microsoft .NET,Framework-based application, ...
... of URAC,s Comprehensive Wellness Accreditation standards , ... announced today that its Board of Directors has approved ... These innovative standards reinforce and support the commitment ... health and productivity of America,s workforce. Comprehensive Wellness ...
... and,president of Ellie,s Meditative Movements, announces the arrival of ... new direction and fulfillment. Meditative,Movements(TM) is the companion ... , Ms. Peterson ... challenge,of raising three children alone, then explains the victory ...
... Erosion and a Dearth of Promising Emerging Therapies Will ... Report from Decision Resources , , ... Decision Resources, one of the world,s leading research ... that, owing to their improvements in safety and efficacy, ...
Cached Medicine News:Health News:Medical societies: Adults need vaccines 2Health News:NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference 2Health News:NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference 3Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 2Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 3Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 4Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 2Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 3Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 4Health News:Meditative Movements(TM), State-of-the-Art Fitness Guidebook, Now Available 2Health News:Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market 2
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: